# Allergy Therapeutics Publishes New Data Validating its Patented Adjuvant, Microcrystalline Tyrosine

- Link: https://www.directorstalkinterviews.com/allergy-therapeutics-publishes-new-data-validating-patented-adjuvant-microcrystalline-tyrosine/412751011
- Published: 2018-05-14T07:16:51+01:00
- Author: Giles Arbor

**Allergy Therapeutics Plc** ([LON:AGY](https://www.directorstalkinterviews.com/company/allergy-therapeutics/agy.l)),
a leading, fully-integrated commercial biotechnology company specialising in allergy
vaccines, today announces that new data from a study investigating immune responses
produced by microcrystalline tyrosine (MCT®)-based vaccines as compared with conventional
aluminium hydroxide has been published online in The Journal of Immunology. The 
findings demonstrate that, based on its comparable strength and mechanism of Ag-
specific IgG induction and induction of T cell responses, MCT® is a suitable and
flexible alternative to aluminium hydroxide as an adjuvant in both allergen-specific
immunotherapy and infectious disease applications. The study also demonstrated that
MCT®-adjuvanted allergens caused fewer anaphylactic reactions compared with alum-
adjuvanted allergens.

> “These findings provide evidence of the effectiveness of MCT as an adjuvant, confirming
> the mechanism of action underlying its ability to induce a robust and sustained
> immunological response. Additionally, the findings indicated a potentially favourable
> profile for the use of MCT over alum in allergy-specific vaccines,” **said Matthias
> Kramer, M.D., Allergy Therapeutics Plc’ International Medical Director and co-
> author of the paper.** “We believe these data highlight the significance of our
> differentiated proprietary platform technology in the development of our growing
> suite of cutting-edge, globally marketed ultra-short course allergy vaccines.”

This is the first study to report the mechanism of action by which MCT governs the
immunologic response after exposure to an antigen and protection against anaphylaxis
in an allergic model. The results illustrate upregulation of IgG antibody responses
and a higher IgE:IgG ratio in MCT-based immunotherapy compared with Alum-based immunotherapy.
A high IgE:IgG ratio has been reported to be a positive predictive marker for allergen
immunotherapy in humans.

Further evaluation in this study indicated that MCT facilitates robust adaptive 
T cell responses with associated IFN-γ (interferon gamma) and TNF-α (tumour necrosis
factor alpha), which is in line with previous studies illustrating protective efficacy
in influenza and malaria applications1, 2. Meanwhile, studies in a cancer (melanoma)
model are underway.

A link to publication is here: www.jimmunol.org/content/200/9/3151

Share on:
